Tapering Atypical Antidepressants
Have any questions on other atypicals or off-label antidepressants? Submit them in the chat and we’ll cover as many as possible live!
About the Event
Join us for this special session in Outro’s Tapering Series, featuring Dr. Mark Horowitz, Scientific Co-Founder of Outro Health, for a focused discussion on tapering atypical antidepressants—specifically Wellbutrin (bupropion), Desyrel (trazodone), and Remeron (mirtazapine).
While these medications fall outside the SSRI/SNRI category, they still come with their own unique tapering challenges. Dr. Horowitz will review what makes these drugs pharmacologically distinct, how withdrawal symptoms may present differently, and why a hyperbolic tapering strategy still applies. We’ll also explore what clinicians and patients need to know about long-term use and how to approach discontinuation safely.
Can’t make it live? Register anyway and we’ll send you the recording.
🧠 What You’ll Learn
What makes atypical antidepressants like bupropion, trazodone, and mirtazapine different from SSRIs/SNRIs
Why patients can still experience withdrawal symptoms—even from medications considered “milder”
How hyperbolic tapering applies to these medications and what dose-response curves suggest
Practical tips for discontinuation, including dose formulation considerations
How Outro supports tapering these and other antidepressants through clinician-guided care
🎙️ Presenters
Dr. Mark Horowitz, MBBS, PhD
Dr. Horowitz is a Clinical Research Fellow in Psychiatry with the NHS, Visiting Lecturer at King’s College London, and Co-Founder of Outro Health. He is the lead author of the Maudsley Deprescribing Guidelines and co-author of the Royal College of Psychiatrists’ guidelines on stopping antidepressants. His work has reshaped how clinicians and systems approach psychiatric medication discontinuation.
Emma Frati
Emma is a member of the Outro Health team with lived experience of psychiatric polypharmacy during her time at Columbia University. She holds a degree in Behavioral Neuroscience and has worked across psychedelic and wearables research, sleep science, harm reduction, and biotech consulting. Emma brings a unique patient-centered perspective to discussions about tapering and mental health.
About Outro
Outro is a virtual care platform specializing in safe, personalized, antidepressant tapering. Our clinicians use hyperbolic tapering—a neuroscience-backed approach—to help patients discontinue psychiatric medications with greater safety and attention to withdrawal symptoms. Learn more at www.outro.com.